COLL

NASDAQ Healthcare

Collegium Pharmaceutical, Inc. - Common Stock

Drug Manufacturers - Specialty & Generic

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

�� 市场数据

价格	$34.41
成交量	482,874
市值	1.12B
贝塔系数	0.770
RSI（14日）	59.9
200日均线	$39.32
50日均线	$38.41
52周最高	$50.79
52周最低	$25.86
市盈率	19.12
Forward P/E	5.38
Price / Book	3.62